Does Midi Prescribe GLP-1? Yes — Compounded and Brand-Name, and the Price Gap Just Flipped

Yes. Midi prescribes GLP-1 medication in two paths: brand-name prescriptions sent to your pharmacy and compounded injectable or sublingual GLP-1 or dual-action GLP-1/GIP medication when clinically appropriate. Compounded prices currently run $164–$460 per four-week supply, but a $250 self-pay first visit makes the lowest publicly calculable starting amount $414 before labs or follow-up care.

Is Midi's GLP-1 likely to fit you?

Midi is most likely to fit women who want menopause and weight care considered in one clinical platform and who are willing to compare an FDA-approved brand with a clearly labeled compounded route. It is a weak fit when the patient needs a guaranteed prescription, Medicare or Medicaid billing, universal state access, or an all-inclusive $164 starting price.

Midi may be a strong fit if:

• Your weight change showed up alongside hot flashes, broken sleep, mood shifts, or other midlife symptoms, and you want menopause and weight care handled through one clinical platform.
• You want a clinician who can consider both a brand-name pharmacy prescription and a compounded route.
• You want a non-injection option and understand that Midi's sublingual products are compounded and not FDA-approved.
• Your commercial insurance may cover the visit, even though Midi's Custom Rx medication is usually a cash cost.
• You want dose options beyond the strengths sold as FDA-approved products, and your clinician documents why a patient-specific compounded dose is appropriate.

Midi is probably the wrong starting point if:

• You expect a guaranteed prescription in exchange for the visit fee.
• You only want an FDA-approved brand and can get it more cheaply through your insurance, Medicare, or a manufacturer self-pay program.
• You have Medicaid or Medi-Cal; Midi says it cannot treat those patients even on a self-pay basis.
• Your state is excluded by the pharmacy that would dispense your Custom Rx.
• You see “starting at $164” and expect that to cover the consultation, labs, medication, and continued care.

What are the three ways to get a GLP-1 through or alongside Midi?

The three practical routes are Midi Custom Rx, a brand-name prescription written by Midi and filled by a pharmacy, and—for eligible Part D beneficiaries—the Medicare GLP-1 Bridge. They differ more on FDA status, coverage, eligibility, and total starting cost than the headline medication price suggests.

Route	Published medication cost	FDA-approved?	Insurance position	The catch
Midi compounded GLP-1 or GLP-1/GIP	$164–$460 per four weeks	No	Midi says Custom Rx is typically not covered by most plans	Visit, labs, and follow-ups are separate; exact product and state access must be confirmed
Brand-name prescription written by Midi	Depends on the drug, pharmacy, insurance, and current manufacturer terms	Yes, for the exact approved product and use	Your pharmacy benefit may cover it; prior authorization may apply	A prescription does not guarantee coverage, stock, or a particular price
Medicare GLP-1 Bridge	$50 per monthly fill for eligible Part D beneficiaries	Yes	Runs outside the Part D benefit	Strict eligibility and prior authorization; the Midi visit itself is still self-pay because Midi does not bill Medicare

The sharpest comparison is not “compounded versus brand-name” in the abstract. It is your known first-step cost, your eligibility, the exact drug and route, and what happens after the starter price ends.

What does Midi's $164 price leave out?

Midi's lowest published medication price is $164 for four weeks. That number is real. It is also not what a new self-pay patient spends to start.

$250 first visit + $164 lowest medication tier = $414 minimum publicly calculable first-step cost

That is before laboratory testing, before any $150 self-pay follow-up, and before a dose change that moves you into another medication tier. It also assumes a clinician prescribes the lowest-priced sublingual option. A prescription, route, and dose are not guaranteed.

Calculated by The HRT Index. This is arithmetic using Midi's published visit and medication prices. It is not a quote from Midi.

Provider links below are labeled at the point of recommendation. Midi is not currently an HRT Index affiliate, so we do not earn a commission from the direct Midi links. That commercial status does not change the prices, limitations, FDA distinctions, or non-affiliate routes shown here.

See Midi's current GLP-1 pricing and check your options → (Provider link; Midi is not currently an HRT Index affiliate.)

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Does Midi prescribe GLP-1 medication?

Yes, in two distinct channels. Midi says its licensed clinicians can write brand-name GLP-1 prescriptions sent to a pharmacy and can prescribe compounded GLP-1 or dual-action GLP-1/GIP medication when clinically appropriate. Its current compounded offerings include injectable and sublingual routes. Not everyone is a candidate, and paying for the visit does not buy a prescription.^[1]

A prescription is not guaranteed

Midi's own price page says medications are prescribed “when appropriate” and that “not everyone is a candidate.” You are paying for a clinical evaluation, not for a guaranteed product.

Midi's public eligibility guidance describes the usual adult weight-management thresholds as a body mass index above 30, or above 27 with at least one weight-related condition. Those thresholds are not a self-approval test.^[3] The exact product's FDA-approved indication, your medical history, current medications, risk factors, laboratory needs, coverage, and clinician judgment still matter.

If you walk in expecting an automatic yes, you may not get one. We would rather tell you that now than have you find out after a $250 visit.

“GLP-1 care” and “a specific brand” are not the same promise

You may be searching “does Midi prescribe Wegovy?” while a provider page says “we offer GLP-1 care.” Those are different sentences.

What you read	What it actually establishes
“GLP-1 care”	A category of clinical care, not a promise of a particular drug
“Brand-name prescription”	A prescription can be sent to a pharmacy; price, coverage, stock, and prior authorization remain separate
“Compounded GLP-1”	A patient-specific pharmacy preparation that is not FDA-approved
“Dual-action GLP-1/GIP”	A category label; Midi's price table does not publicly name the exact active ingredient behind every row
“Starting at $164”	The lowest four-week medication tier, not the cost of starting care

Which GLP-1 medications can Midi prescribe?

Midi can write brand-name prescriptions and advertises compounded GLP-1 and compounded dual-action GLP-1/GIP categories. Its public education pages name Wegovy and Zepbound as examples of drugs approved for weight management. The current price table does not identify the active ingredient behind every compounded category, so confirm the exact drug before paying for it.^[2]

Wegovy, Zepbound, Ozempic, and Mounjaro are not interchangeable labels

The approval belongs to the exact product, route, dose, and indication—not just to a molecule or drug family.^{[14][15][16][17]}

Brand	Ingredient	Relevant FDA position
Wegovy	Semaglutide	FDA-approved in specified formulations for chronic weight management; other approved indications also exist
Ozempic	Semaglutide	FDA-approved for type 2 diabetes and specified cardiovascular and kidney-risk uses; not FDA-approved for general weight loss
Zepbound	Tirzepatide	FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity
Mounjaro	Tirzepatide	A different brand with a different FDA-approved indication; do not treat the name as interchangeable with Zepbound

A clinician may discuss off-label prescribing, but this page will not turn that possibility into a promise.

Does Midi prescribe semaglutide?

Midi publishes a product monograph titled Semaglutide for a compounded injectable product. The monograph says the formulation includes vitamin B12 as a component, describes subcutaneous injection, and lists refrigeration and missed-dose instructions.^[5]

That monograph supports one narrow conclusion: Midi publicly documents an injectable compounded semaglutide formulation containing B12. It does not establish that every GLP-1 price row, every sublingual product, or every dual-action product uses the same ingredient, pharmacy, concentration, or formula.

Does Midi prescribe tirzepatide?

Midi can write brand-name prescriptions and advertises a dual-action GLP-1/GIP compounded category. Its public price table does not name the active ingredient behind that category. Ask the clinician to put the exact drug, concentration, pharmacy, route, and added ingredients in your visit notes before you pay for the medication.

Injection or drops under the tongue?

Midi advertises both injectable and sublingual compounded options. That is a real route choice, but neither compounded route is FDA-approved.

Question	Injectable compounded route	Sublingual compounded route
Advertised by Midi	Yes	Yes
Lowest published price	$165.90 per four weeks	$164 per four weeks
FDA-approved	No	No
Public product detail	Midi has an injectable semaglutide monograph; the label on your prescription controls	The public price table does not identify the exact formulation behind each sublingual category
Main question to ask	What is the concentration, dose in milligrams, volume or units, storage rule, and dispensing pharmacy?	What is the exact active ingredient, formulation, dose, administration method, and reason for this route?

There is no public head-to-head trial of Midi's sublingual compounded product against an FDA-approved injectable. Do not assume equal exposure, equal dosing, or equal results.

And before you decide that a compounded sublingual product is the only way to avoid injections, price the FDA-approved Wegovy tablet path too. It is a tablet, not a compounded drop, and its price changes across the titration schedule.

What exactly is Midi's compounded GLP-1—and who dispenses it?

Midi's public pages disclose more than the headline price, but not enough to identify every product in advance. The injectable semaglutide monograph names semaglutide, shows vitamin B12 as a formulation component, and directs questions about the source of the information to pharmacists at Belmar Pharmacy. Midi's separate Custom Rx help page names Belmar and Precision Compounding as pharmacy partners.^[5][6]

That is not the same as proof that Belmar fills every current GLP-1, GLP-1/GIP, injectable, or sublingual order. The dispensing pharmacy, active ingredient, concentration, route, and added ingredients should appear on the prescription and product label. Confirm them for your order.

What Midi's public pages establish—and what they do not

Question	Publicly established as of August 2026?
Does Midi offer compounded GLP-1 care?	Yes
Does it offer injectable and sublingual routes?	Yes
Does Midi publish an injectable semaglutide monograph?	Yes
Does that monograph identify vitamin B12 as a formulation component?	Yes
Does Midi name pharmacy partners for Custom Rx?	Yes: Belmar and Precision Compounding
Does the price table name the active ingredient behind all 32 rows?	No
Does the monograph prove which pharmacy will fill your specific prescription?	No
Is the concentration and dose-measurement method public before prescribing?	No—confirm on the prescription and label
Is every current compounded route available in every state?	No—pharmacy exclusions apply

About the “503A-accredited” wording

Midi's price page describes partner pharmacies as “licensed and 503A-accredited.” Section 503A is a category in federal compounding law, not an accreditation. A 503A pharmacy compounds patient-specific prescriptions and is primarily overseen by its state board of pharmacy, while accreditation and certification are separate credentials.

That terminology mistake does not prove the pharmacy is illegitimate. It does mean you should verify the concrete facts that matter: the pharmacy name, its license for your state, the label, the exact formulation, and the prescription written for you.

See Midi's current dose options and ask which pharmacy would fill yours → (Provider link; Midi is not currently an HRT Index affiliate.)

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

See how Find My HRT Path handles private health answers.

How much does Midi's GLP-1 really cost?

Midi currently publishes 32 dose-level prices from $164 to $460 per four-week supply, with shipping and supplies included and no membership fee. A self-pay first visit is $250 and a self-pay follow-up is $150. The lowest publicly calculable new-patient amount is $414 before labs or continued care.^[1][4]

All 32 published Midi GLP-1 prices

The tables below reproduce Midi's public price table as verified August 14, 2026. The category names are Midi's. Do not infer an unnamed active ingredient from a category label.

Compounded GLP-1, injectable

Dose	Price per four weeks
0.1 mg	$165.90
0.25 mg	$165.90
0.35 mg	$165.90
0.5 mg	$165.90
0.75 mg	$270.90
1 mg	$270.90
1.25 mg	$270.90
1.5 mg	$270.90
1.75 mg	$340.00
2 mg	$340.00
2.5 mg	$355.00

Compounded dual-action GLP-1/GIP, injectable

Dose	Price per four weeks
1.25 mg	$210.00
2.5 mg	$210.00
3.75 mg	$285.00
5 mg	$285.00
6.25 mg	$285.00
7.5 mg	$375.00
10 mg	$375.00
11.25 mg	$375.00
12.5 mg	$375.00
13.75 mg	$434.00
15 mg	$434.00

Compounded GLP-1, sublingual

Dose	Price per four weeks
0.075 mg	$164.00
0.15 mg	$235.00
0.24 mg	$235.00
0.4 mg	$255.00
0.8 mg	$275.00

Compounded dual-action GLP-1/GIP, sublingual

Dose	Price per four weeks
1 mg	$209.00
3.5 mg	$245.00
5 mg	$370.00
6 mg	$370.00
7 mg	$460.00

Four starting-floor calculations Midi does not assemble for you

Lowest-priced route	Self-pay first visit	Lowest four-week medication tier	Known starting floor
Sublingual GLP-1	$250	$164.00	$414.00
Injectable GLP-1	$250	$165.90	$415.90
Sublingual GLP-1/GIP	$250	$209.00	$459.00
Injectable GLP-1/GIP	$250	$210.00	$460.00

Calculated by The HRT Index. These totals use the lowest row in each route and Midi's current self-pay initial-visit price. They do not include labs, a $150 self-pay follow-up, dose increases, or medication from an outside pharmacy. Your actual prescription may begin at another dose or route.

The price ladder is not proportional to the dose ladder

Two examples from Midi's published injectable GLP-1 table:

• Moving from 0.5 mg to 0.75 mg is a 50% dose increase and a 63% price increase, from $165.90 to $270.90.
• Moving from 2 mg to 2.5 mg is a 25% dose increase and a little over a 4% price increase, from $340 to $355.

That does not tell you which dose is right. It tells you why the phrase “starts at $164” cannot predict your 90-day budget.

What the displayed price includes

Midi says its displayed Custom Rx prices include shipping and supplies and that there is no membership fee. The visit, laboratory testing, and continued clinical care are separate.^[1]

Midi's help center says Custom Rx delivery is anticipated within three to five business days after payment is processed. Treat that as a provider-stated expectation, not a guaranteed arrival date.^[8]

Is Midi cheaper than getting Wegovy or Zepbound directly?

Sometimes, but no longer by default. The cheapest current FDA-approved cash tier is $149 for oral Wegovy's starter 1.5 mg dose and, through August 31, 2026, its 4 mg titration dose—$15 less than Midi's lowest $164 compounded tier. But oral Wegovy maintenance is 25 mg at $299, so $149 is not the ongoing maintenance price.^[11][14]

This is a cash-path comparison, not a dose-equivalence table. The products, routes, formulations, titration schedules, approval status, and clinical uses are different.

Cash route	Current published price	FDA-approved?	What changes the number
Wegovy tablet, 1.5 mg starter	$149	Yes	Starter month, not maintenance
Wegovy tablet, 4 mg titration	$149 through Aug. 31, 2026; then $199	Yes	Temporary offer; not maintenance
Wegovy tablet, 9 mg titration	$299	Yes	Later titration month
Wegovy tablet, 25 mg maintenance	$299	Yes	Ongoing published self-pay tier
Midi compounded sublingual GLP-1	$164–$275	No	Dose tier; consultation and follow-up separate
Midi compounded injectable GLP-1	$165.90–$355	No	Dose tier; consultation and follow-up separate
Wegovy injection, qualifying new-patient offer	$199 for the first two fills	Yes	Applies to specified starter doses through Dec. 31, 2026; then the standard tier
Wegovy injection, standard self-pay	$349	Yes	Current published standard cash tier
Zepbound 2.5 mg	$299	Yes	Starting dose; not a maintenance dose
Zepbound 5 mg	$399	Yes	Current self-pay tier
Zepbound 7.5–15 mg	$449 when refilled within 45 days	Yes	Late refills move to higher regular prices
Midi compounded dual-action GLP-1/GIP	$209–$460	No	Route and dose tier; visit and follow-up separate
Medicare GLP-1 Bridge	$50	Yes	Only for eligible Part D beneficiaries after prior authorization

The price gap flipped—but only at specific points

The old shorthand was that compounded medication is the cheap route. That is no longer reliable.

• The approved oral Wegovy starter tier is cheaper than every Midi compounded tier.
• The standard $299 oral Wegovy maintenance tier is cheaper than some Midi rows and more expensive than others.
• Wegovy's $349 standard injection tier is below Midi's $355 top GLP-1 injectable row but above Midi's lower rows.
• Zepbound's current self-pay tiers can undercut some of Midi's upper dual-action rows, but the exact comparison changes by dose and refill timing.
• Insurance or Medicare can move the approved product far below any cash-compounded price.

So the honest reason to consider compounding is not “it is always cheaper.” The potential case is patient-specific dose or route flexibility when a clinician determines an FDA-approved product cannot meet that patient's documented need. If price is the reason, compare the exact current approved-product program first.

NovoCare's current cash terms allow people with commercial or government-funded insurance to self-pay for eligible Wegovy prescriptions without submitting a claim. Lilly's Zepbound savings and self-pay paths have their own eligibility and refill rules. Check the manufacturer's current terms on the day you fill.^[12][13]

If you meet the approved criteria and want the named FDA-approved drug: ask a prescriber—including a Midi clinician—whether an approved brand fits, then verify your insurance and the manufacturer's current cash price.

If you need a patient-specific dose or route that an approved product cannot provide: ask what exact compounded formulation is being proposed, why it makes a meaningful difference for you, and what it will cost after the first month.

Compare Midi's current GLP-1 routes with the approved-brand path → (Provider link; Midi is not currently an HRT Index affiliate.)

Will insurance cover a Midi GLP-1 visit or medication?

Insurance may cover the Midi visit, but that does not settle the medication bill. Midi is in-network with many PPO plans, subject to the exact plan, clinician, state, copay, deductible, and coinsurance. Its Custom Rx help page says compounded prescriptions are typically not covered by most insurance plans, not that reimbursement is impossible in every case.^[4][7]

Keep the decisions separate:

Question	Who answers it?
Is my Midi clinician in network for this visit?	Midi and your health plan
What will I owe for the visit?	Your plan after copay, deductible, and coinsurance rules
Is a brand-name GLP-1 on my formulary?	Your pharmacy benefit
Does the brand require prior authorization or step therapy?	Your health plan
Is Midi Custom Rx reimbursable under my plan?	Your plan; Midi says most plans typically do not cover it
Can I use HSA or FSA funds?	Midi says Custom Rx may be paid with HSA/FSA when the plan permits online transactions
Are labs included?	No universal bundle is published; ask how the lab will be ordered and billed

Four questions to ask your insurer

1. Is Midi Health—and the clinician I would see—in network for my exact plan and state?
2. Is Wegovy or Zepbound on my current formulary for my diagnosis, and what clinical criteria apply?
3. Is prior authorization or step therapy required?
4. Does my plan exclude weight-management medication entirely?

Write down the representative's name, date, and call reference number. That is not bureaucracy for its own sake. It is the record you will need if a later answer conflicts with what you were told.

HSA and FSA

Midi says HSA/FSA funds may be used for Custom Rx purchases if the account permits online transactions. That is not the same as a universal tax-eligibility ruling for every account or every expense. Confirm with your plan administrator when the amount is material.^[7]

Check whether Midi is in network and what your visit may cost → (Provider link; Midi is not currently an HRT Index affiliate.)

What changes if I have Medicare or Medicaid?

Medicare and Medicaid produce two different answers. Midi says it does not bill Medicare, but Medicare beneficiaries can use Midi on a self-pay basis. Midi says it cannot treat Medicaid or Medi-Cal patients even if they offer to self-pay. The federal Medicare GLP-1 Bridge may make an approved product much cheaper for eligible Part D beneficiaries.^[4]

If you have Medicare Part D

The Medicare GLP-1 Bridge began July 1, 2026 and runs through December 31, 2027. Eligible Part D beneficiaries pay a $50 copay per monthly fill for covered formulations of Wegovy, Foundayo, and the Zepbound KwikPen after prior authorization. The Bridge operates outside the normal Part D benefit: the deductible does not apply, the $50 does not count toward true out-of-pocket costs, and the low-income subsidy does not reduce it.^[18]

Not every Medicare beneficiary qualifies. CMS requires an eligible Part D plan, use for weight reduction, continued lifestyle modification as clinically appropriate, prior authorization, and specified clinical criteria. Some diagnoses route the drug through ordinary Part D rather than the Bridge.

Midi's visit is not covered by Medicare. But “Midi does not bill Medicare” does not automatically mean a Midi clinician is legally unable to write a Bridge prescription or submit the prior authorization. CMS says a Bridge prescriber does not need to be enrolled in Medicare, although the prescriber must not be on the Preclusion List.^[19]

The question to ask Midi before paying is direct:

“If I meet the Medicare GLP-1 Bridge criteria, will my clinician submit the prescription and Bridge prior authorization even though the visit itself is self-pay?”

Midi does not publish that workflow. Confirm it first. If the answer is no, use a prescriber who participates in the Bridge process. Go to Medicare's GLP-1 Bridge page or call 1-800-MEDICARE for the current eligibility path.

If you have Medicaid or Medi-Cal

Midi says it cannot treat Medicaid or Medi-Cal patients at this time—even as self-pay patients. That is the provider-level stop.

Your next route is an in-network clinician and your state benefit. Coverage for obesity medications varies by state and plan. Do not assume a commercial savings card will replace Medicaid coverage; use the program terms and your state plan's rules.

Is Midi's GLP-1 available in my state?

Midi's broader virtual care is advertised nationally, but its Custom Rx pharmacy access has specific exclusions. Midi's current help page says Precision Compounding can ship Custom Rx to every state except South Carolina and Arkansas, while Belmar can ship to every state except Arkansas and Alabama.^[6]

That is more useful than “availability varies,” but it still does not tell you which pharmacy or formulation will be selected for your prescription.

State	Precision Compounding listing	Belmar listing	What it means for a Midi Custom Rx inquiry
Arkansas	Not available	Not available	Both pharmacy partners named on Midi's current help page exclude Arkansas; ask about a brand-name pharmacy route or another treatment option
Alabama	Listed as available	Not available	Availability depends on the selected pharmacy and product
South Carolina	Not available	Listed as available	Availability depends on the selected pharmacy and product
Other states	Listed as available	Listed as available	Still confirm the exact product, route, pharmacy, and current shipping eligibility

This table is about the two Custom Rx partners Midi names. It does not guarantee that every GLP-1 formulation is available through both partners or that either partner fills your exact order.

Send this before you book:

“Can a Midi clinician evaluate me for GLP-1 care in my state, which pharmacy would dispense the exact formulation you are considering, and can that pharmacy currently ship it to my address?”

Three clauses. Ask all three.

Is Midi's compounded GLP-1 FDA-approved, and is compounding legal in 2026?

Midi's compounded GLP-1 products are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and a compounded product is not an FDA-approved generic. Compounding remains lawful under defined federal and state conditions; it is not a blanket legal substitute for a commercially available approved drug.^[20]

What “not FDA-approved” means

FDA approves a specific drug product: its formulation, route, strength, manufacturing controls, labeling, and approved use. That approval does not transfer to a patient-specific compounded preparation.

A state-licensed pharmacy is not an “FDA-approved pharmacy.” A compounded product is not automatically “the same,” “generic,” or “clinically equivalent” to Wegovy or Zepbound. This page will not use those descriptions.

FDA says compounded drugs should generally be used when a patient's medical need cannot be met by an FDA-approved product. That is the decision to resolve with the prescriber—not with marketing copy.

What changed after the shortages ended

Date	Regulatory event
December 2024	FDA determined the tirzepatide injection shortage was resolved
February 21, 2025	FDA determined the semaglutide injection shortage was resolved
March 5, 2025	FDA's enforcement-discretion period ended for most 503A tirzepatide copies
March 19, 2025	FDA's enforcement-discretion period ended for 503B tirzepatide copies
April 24, 2025	FDA's enforcement-discretion period ended for most 503A semaglutide copies
May 22, 2025	FDA's enforcement-discretion period ended for 503B semaglutide copies
April 30, 2026	FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; as of August 14, 2026, the located FDA action remains a proposal, not a final determination

The shortage ending did not ban every patient-specific compounded prescription. It removed the broad shortage-based pathway for making essentially copies at scale.^[21][22]

For a 503A patient-specific prescription, federal law restricts products that are essentially copies of commercially available drugs. A prescriber may identify a change that produces a significant difference for the individual patient. An intermediate dose, a different route, or an added ingredient can be part of that analysis—but none is an automatic legal safe harbor merely because it appears on a price table.

The dangerous shortcut is: “Need a microdose or fall below the approved criteria? Use compounded.” That is not a safe or accurate rule. Compounding is not a workaround for clinical eligibility. The clinician still has to decide that the prescription is appropriate and that the patient-specific formulation has a legitimate basis.

Ask what happens if the formulation becomes unavailable

A compounded route can change when FDA policy, pharmacy capacity, state law, or product availability changes. Before starting, ask whether the clinician would consider an FDA-approved alternative and whether a new visit, prior authorization, or dose transition would be required. Do not assume an automatic switch.

Is Midi's compounded GLP-1 safe?

No website can certify that a compounded shipment is safe before the prescription, pharmacy, label, concentration, package condition, and instructions exist. What can be verified is whether Midi requires a clinician, identifies that its Custom Rx is not FDA-approved, names pharmacy partners, and provides continued clinical contact. The rest has to be checked on the prescription and at delivery.

What we could verify online versus what you must verify on the label

Safety question	What the public record establishes
Is a licensed clinician involved?	Midi says a clinical visit and clinician decision are required
Does Midi disclose that the compounded product is not FDA-approved?	Yes
Is the active ingredient public for every price row?	No
Does Midi publish an injectable semaglutide monograph?	Yes
Does that monograph identify B12 as a formulation component?	Yes
Are pharmacy partners named?	Yes, but the public pages do not assign every GLP-1 row to a specific pharmacy
Is your concentration, volume, or unit conversion public?	No—your prescription and label must establish it
Did the package arrive intact and at an acceptable temperature?	Only you and the dispensing pharmacy can assess that after delivery

The FDA's current counterweight

FDA's concerns about unapproved GLP-1 products are current, not historical:

• As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA says it is not always possible to determine whether the product caused the event, and reports are likely incomplete because state-licensed 503A pharmacies generally are not required to report adverse events to FDA.
• FDA has reported dosing errors, including some requiring hospitalization, when patients or clinicians miscalculated doses or measured medication from multidose vials.
• FDA warns that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved drugs and says it is not aware of a lawful basis for using those salt forms in compounding.
• FDA has identified fraudulent products carrying pharmacy names that did not make them or names of nonexistent pharmacies.^[23]

Ask two questions before the first dose:

1. What exact form of the active ingredient is on this prescription and label?
2. Show me the dose in milligrams and the exact volume or number of units I must measure.

Delivery-day checklist

• Does the package name the dispensing pharmacy and match the pharmacy you were told to expect?
• Does the patient's name, drug, concentration, dose, and route match the prescription?
• Are the instructions complete and readable?
• Is the package damaged, leaking, unusually warm, or missing cold-chain materials when refrigeration is required?
• Is the beyond-use date visible?
• Do the dose units match what the clinician taught you?

If a refrigerated product arrives warm or damaged, do not inject it until the dispensing pharmacy confirms whether it remains usable. FDA has received complaints about compounded GLP-1 products arriving warm.^[23]

Side effects and who should not take it

Midi's injectable semaglutide monograph lists nausea, diarrhea, belching or gas, bloating, constipation, heartburn, and vomiting among possible effects. It also tells patients to contact a clinician about warning symptoms involving the thyroid, gallbladder, pancreas, vision, low blood sugar, fast heartbeat, and mood changes. The exact approved product label and your prescription information should control for the drug you receive.^[5]

One line from Midi's own monograph deserves to remain undiluted:

Midi lists “currently struggling with an eating disorder” among the reasons not to use its compounded injectable semaglutide product.

If food and weight have ever become unsafe territory for you, tell the clinician before the conversation goes any further. Hiding it does not preserve access. It changes the risk without changing the truth.

The monograph also lists pregnancy or breastfeeding, personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis history, tachyarrhythmias, and allergy to semaglutide, vitamin B12, or another formulation component among the issues it says should prevent or change use. This is not an exhaustive self-screening tool. A clinician must review your history and the current labeling for the exact product.

Who qualifies, and what happens at a Midi GLP-1 visit?

A Midi clinician decides whether treatment is appropriate—not this page, a quiz, or a BMI number by itself. Midi says it reviews health history, medications, risks, and goals; may order targeted labs; and provides follow-up care. The public GLP-1 prices do not include laboratory costs.^[2][10]

Before the visit, have these ready

• Your insurance card and pharmacy-benefit information.
• Every prescription, over-the-counter medication, and supplement you take.
• Recent laboratory results and relevant diagnoses.
• Your weight history and what you have already tried.
• Any history involving diabetes, pancreatitis, gallbladder disease, severe gastrointestinal symptoms, thyroid cancer syndromes, eating disorders, pregnancy, or breastfeeding that the clinician should review.
• Your state and preferred pharmacy.
• Your budget ceiling for the first month and for maintenance.
• Whether you will consider a compounded product or want an FDA-approved brand only.

Decide that last preference before the visit. You can change your mind after hearing the clinical case, but you should not discover the FDA distinction while entering a card number.

During the visit, ask these six questions

1. Which exact product are you considering—brand-name or compounded?
2. If compounded, what are the active ingredient, salt form, concentration, route, added ingredients, and dispensing pharmacy?
3. What dose would I start on, and what is that exact four-week medication price?
4. Are labs needed, can recent outside results be reviewed, and how will any new tests be billed?
5. Would an FDA-approved product meet my need, and what would my insurance or the manufacturer charge?
6. What is the plan if the medication is unavailable, unaffordable, poorly tolerated, or no longer appropriate?

On labs

Midi says clinicians may order labs when appropriate. It does not publish one universal GLP-1 panel, one universal laboratory price, or a promise that every patient can reuse outside results. The accurate answer is: labs are possible, clinician-directed, and not included in the published medication price.

After the prescription

The next steps depend on the route:

• A brand-name prescription goes to the pharmacy, where stock, prior authorization, insurance, and copay are resolved.
• A Custom Rx is paid through Midi's prescription flow and fulfilled by a partner pharmacy.
• Midi says Custom Rx is generally expected within three to five business days after payment processing.
• Continued care may involve messages, laboratory review, dose changes, side-effect management, and follow-up visits.
• Midi says follow-up visits are $150 self-pay, or subject to the patient's insurance cost sharing when covered.

If you need to cancel or reschedule a visit, Midi asks for at least 24 hours' notice to avoid a cancellation fee. Its help page does not state the fee amount, so confirm that amount before relying on the policy.^[9]

What happens if you stop?

Stopping a GLP-1 is a clinical decision, not a cancellation trick. Weight regain after withdrawal has been documented in trials of approved GLP-1 therapy, although individual outcomes vary. Ask about the likely duration, maintenance strategy, follow-up plan, and what the clinician would do if cost or access changes before starting.^[24]

Can Midi handle hormone therapy and a GLP-1 together?

Midi offers menopause care and weight care through the same platform, and that is its strongest fit case. A woman whose weight change arrived beside hot flashes, sleep disruption, mood changes, or other midlife symptoms may value one care relationship that can see both problems. That does not mean HRT and a GLP-1 will be prescribed together—or that one treats the other.^[2]

The emotional truth is simple: you may be tired of explaining one body to two companies that never speak to each other.

Midi's model can reduce that fragmentation. But confirm the operational version rather than assuming it:

• Will one clinician oversee both care plans?
• Can both issues be addressed in one visit, or are separate visits required?
• Are there separate charges?
• Will laboratory results be shared across the plan?
• Who reviews possible interactions and side effects?
• What happens if insurance covers one part but not the other?

GLP-1 drugs can delay gastric emptying and may affect the absorption of oral medications. Midi's monograph tells patients to disclose every medication and supplement. Give the full list to both the clinician and pharmacist rather than trying to predict an interaction yourself.^[5]

Related reading: what online HRT costs in 2026 · weight care in midlife · Midi Health review · best online HRT providers

What are the real drawbacks of getting a GLP-1 through Midi?

Five verified limits matter before you pay. A prescription is not guaranteed. The $164 headline excludes the visit, labs, and follow-up care. Custom Rx is typically not covered by most insurance. The public price table does not name the active ingredient behind every compounded category. Pharmacy-specific state exclusions can block a Custom Rx route.

Here is the one that matters most:

Midi will show you 32 compounded dose prices without naming the active ingredient behind every row. Its separate injectable semaglutide monograph supplies real information, but it does not identify every current GLP-1/GIP or sublingual formulation, and it does not prove which partner pharmacy will fill your order.

If what you want is a named FDA-approved drug with an official label and a cash price you can verify directly, ask for that route first. At several current starter or upper-tier comparisons, the approved product is no longer the expensive default.

If what you want is integrated menopause and weight care, a patient-specific route, or a dose an approved presentation does not sell, Midi still has a real case. The clinician—not the pharmacy checkout—is the value. The case only holds if the exact formulation, rationale, cost, and backup plan are clear before you pay.

The other limits do not need softer language:

• Custom Rx is usually a continuing cash cost. “No membership fee” does not mean “no recurring bill.”
• The price can jump between tiers. Budget beyond the cheapest row.
• State access depends on the partner pharmacy. Arkansas is excluded by both partners on Midi's current help page; Alabama and South Carolina depend on which partner is involved.
• Compounded is not FDA-approved. If FDA approval is your non-negotiable, use the brand-name path.
• A visit can end without a GLP-1 prescription. That is the point of a clinical evaluation, and it is still a financial risk you should know before booking.

If those tradeoffs still fit what you are looking for, you have enough information to take the medical step without pretending it is a simple purchase.

Check Midi's current pricing, coverage, and state path → (Provider link; Midi is not currently an HRT Index affiliate.)

Which GLP-1 route should you take?

Coverage and clinical eligibility narrow the route before preference does. Medicare, Medicaid, approved-product eligibility, insurance, state access, route preference, and the need for a patient-specific formulation should drive the decision—not an affiliate payout and not the lowest headline price.

Your situation	First route to examine	Why	What could change it
Eligible for the Medicare GLP-1 Bridge	Bridge-covered FDA-approved drug	$50 monthly copay after prior authorization	You do not meet the Bridge criteria, or the use belongs under ordinary Part D
Medicaid or Medi-Cal	In-network clinician and state benefit	Midi says it cannot treat you, even self-pay	Your state benefit and provider network determine access
Commercial insurance may cover Wegovy or Zepbound	Brand-name pharmacy benefit first	FDA-approved and potentially cheaper than cash compounding	Formulary exclusion, denial, supply, or unaffordable cost sharing
No useful coverage but you meet the approved indication	Compare manufacturer self-pay terms	Current approved cash tiers can undercut some compounded tiers	Promotional expiration, titration price, or manufacturer eligibility terms
Menopause symptoms and weight care need one clinical plan	Midi evaluation; ask about approved brand first and compounded only when justified	Integrated care is Midi's strongest differentiator	State exclusion, cost, clinical fit, or preference for in-person care
A commercially available approved dose or route cannot meet a documented patient-specific need	Clinician-evaluated compounded route	Patient-specific flexibility may be the legitimate reason to compound	The clinician finds no appropriate basis, the pharmacy cannot ship, or the formulation changes
You want to avoid injections	Price FDA-approved oral Wegovy and compare Midi's sublingual option without assuming equivalence	Both avoid needles but are not the same product or route	Clinical fit, titration, cost, evidence, and availability

The rule to remove from your thinking is “below the brand criteria means compounded.” It does not. Below-label use and compounding are clinical and legal questions, not a consumer workaround.

What should you ask before you pay?

Six answers close the remaining gap. Every question exists because a public price page cannot decide your exact prescription, pharmacy, coverage, state access, or backup plan.

1. What exact product would you prescribe—brand-name or compounded?
2. If compounded, what are the active ingredient, salt form, concentration, route, added ingredients, and pharmacy?
3. Can that pharmacy dispense and ship this exact formulation to my state?
4. What dose would I start on, and what is that dose's exact four-week price?
5. What will I owe for the visit, labs, medication, and expected follow-ups over the first 90 days?
6. If the compounded formulation becomes unavailable or an approved brand is cheaper, what is the transition plan?

Print them. Put them in your notes app. A clinician who answers all six clearly is giving you the information needed for informed consent and an informed financial decision.

You do not need another vague promise that GLP-1 care is available. You need six exact answers tied to your prescription.

Book a Midi evaluation with the six-question list in hand → (Provider link; Midi is not currently an HRT Index affiliate.)

Still unsure whether Midi is the right starting point? Use Find My HRT Path to match the care route to your symptoms, state, treatment preferences, risk history, and coverage—and to flag when online care is not the right place to begin.

What did The HRT Index actually verify?

We verified the current public medication categories, all 32 dose prices, visit fees, shipping language, insurance language, pharmacy-state exclusions, the injectable semaglutide monograph, manufacturer self-pay terms, Medicare Bridge rules, and current FDA compounding materials. We did not enroll, receive a prescription, complete checkout, inspect a shipment, or test cancellation.

What we did

• Read Midi's GLP-1 pricing, weight-management, pricing-and-insurance, billing, Custom Rx insurance, pharmacy-state, shipping, cancellation, and injectable semaglutide pages.
• Transcribed and recounted all 32 public dose rows.
• Reproduced the $414, $415.90, $459, and $460 first-step floors from Midi's published numbers.
• Compared current approved-product cash paths without treating doses or formulations as equivalent.
• Checked current FDA materials on compounded GLP-1 dosing errors, salt forms, adverse-event reports, shortage enforcement dates, and the pending 503B bulks-list proposal.
• Checked current CMS Medicare GLP-1 Bridge eligibility, cost, covered products, program dates, and prescriber rules.

What we could not establish publicly

• Which active ingredient sits behind every unnamed Midi GLP-1 or GLP-1/GIP price row.
• Which partner pharmacy fills every route and product.
• The exact concentration, dose-measurement instructions, and added ingredients for a future patient's prescription.
• A complete product-by-product state matrix beyond Midi's current pharmacy-partner exclusions.
• Whether Midi will submit a Medicare GLP-1 Bridge prior authorization for a self-pay patient.
• A universal lab panel or lab price.
• The cancellation-fee amount.
• The final out-of-pocket amount for an insured visit or pharmacy prescription.

Provider-stated versus verified

Claim	Label	Status as of August 2026
Midi can prescribe brand-name GLP-1 products to a patient's pharmacy	Verified on Midi's current public page	Confirmed
Midi offers compounded injectable and sublingual GLP-1 and GLP-1/GIP categories	Verified on Midi's current public price page	Confirmed
Midi publishes 32 dose-level prices from $164 to $460	Transcribed from provider table	Confirmed
Shipping and supplies are included; no membership fee	Provider-stated on price page	Confirmed as published
Initial self-pay visit is $250; follow-up is $150	Verified on provider pricing page	Confirmed
Lowest publicly calculable self-pay start is $414	Calculated by The HRT Index	Reproducible arithmetic
Custom Rx is never covered by insurance	Not supported by Midi's current policy	Midi says typically not covered by most plans
Midi publishes no state information	Outdated	Current partner exclusions are published
Every compounded GLP-1 is semaglutide made by Belmar	Not established by public sources	Do not assume; confirm the product and pharmacy
Midi's injectable semaglutide monograph identifies semaglutide and B12	Verified on provider monograph	Confirmed
Compounded products are FDA-approved generics	False	Explicitly rejected
The $149 Wegovy tablet price is ongoing maintenance pricing	Incomplete	It is a starter/temporary titration price; current maintenance tier is $299
Medicare Bridge requires a Medicare-enrolled prescriber	False	CMS says enrollment is not required, subject to the Preclusion List
Your prescription, dose, final price, coverage, and pharmacy	Patient-specific	Confirm during intake, prescribing, and fulfillment

This page was produced under The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule.

What do patients say about Midi's care?

Midi publishes positive patient comments about access and listening, but company-selected testimonials are not evidence that GLP-1 treatment is safe, effective, or typical. We use them only to show the care experience Midi chooses to highlight.^[4]

“Midi was so easy: I got a same day appointment and they took my insurance.” — Victoria W., published by Midi

“For the first time, someone actually listened to me during my visit without typing or multitasking. It felt like a luxury to be genuinely heard.” — Shyla D., published by Midi

These are provider-published testimonials. We do not know whether the speakers were compensated, and individual experiences do not establish typical access, insurance results, prescribing decisions, or medical outcomes.

We did not use Midi's selected weight-loss outcomes as proof that a medication works, and we did not identify an independently verified review set specific enough to establish the experience of Midi's current GLP-1 program.

Related GLP-1, weight-care, and Midi guides

Compare approved versus compounded routes, integrated menopause care, costs, and the questions to ask before a prescription.

• Compare online menopause clinics with GLP-1 care
• Read about taking HRT and GLP-1 together
• Compare HRT and GLP-1 for menopause weight gain
• Read the midlife weight-care guide
• Read the full Midi Health review
• See whether Midi prescribes progesterone
• See whether Midi prescribes vaginal estrogen
• Find your best-fit HRT path

What else do women ask about whether Midi prescribes GLP-1?

The remaining questions are about named drugs, total cost, insurance, Medicare, state access, labs, pharmacy identity, sublingual medication, and what happens after treatment starts. The answers below are deliberately direct so each one can stand alone without blurring FDA-approved and compounded products.

Does Midi prescribe Ozempic or Wegovy?

Midi says its clinicians can write brand-name GLP-1 prescriptions sent to a pharmacy and names Wegovy in its weight-management materials. Ozempic is not FDA-approved for general weight loss; its approved uses concern type 2 diabetes and specified cardiovascular and kidney-risk indications. The exact prescription depends on the clinician, indication, coverage, and pharmacy.

Does Midi prescribe tirzepatide or Zepbound?

Midi can write brand-name prescriptions and advertises a dual-action GLP-1/GIP compounded category. Zepbound is an FDA-approved tirzepatide brand for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Midi's public compounded price table does not name the ingredient behind every dual-action row, so confirm the exact product.

Is Midi's compounded semaglutide the same as Wegovy?

No. Midi's injectable semaglutide monograph describes a compounded formulation that includes vitamin B12. Compounded drugs are not FDA-approved, are not FDA-approved generics, and should not be described as the same or clinically equivalent to Wegovy.

How much does Midi's GLP-1 cost per month?

Midi publishes 32 prices from $164 to $460 per four-week supply, with shipping and supplies included. A self-pay first visit is $250 and a self-pay follow-up is $150. The lowest publicly calculable first-step amount is $414 before labs or continued care.

Is the $164 price all-inclusive?

No. It is the lowest four-week medication tier. It does not include the visit, labs, follow-up care, or a future move to a higher-priced dose.

Does insurance cover Midi's compounded GLP-1?

Midi says Custom Rx prescriptions are typically not covered by most insurance plans. Some plans may permit reimbursement documentation, and HSA/FSA use may be possible when the account permits online transactions. Verify your plan rather than treating “typically not covered” as a universal denial.

Can insurance cover a brand-name prescription written by Midi?

Possibly. Visit coverage and pharmacy coverage are separate. Your pharmacy benefit determines formulary status, prior authorization, step therapy, deductible, copay, and exclusions for the exact brand.

Does Medicare cover a GLP-1 prescribed by Midi?

Midi does not bill Medicare for its visit, so the visit would be self-pay. Eligible Part D beneficiaries may access specified approved drugs through the $50 Medicare GLP-1 Bridge. CMS says a prescriber does not need to be enrolled in Medicare to prescribe or submit the Bridge authorization, but Midi does not publicly state whether it will handle that workflow. Ask before paying.

Does Midi accept Medicaid or Medi-Cal?

No. Midi says it cannot treat Medicaid or Medi-Cal patients at this time, even as self-pay patients.

What states can receive Midi Custom Rx?

Midi says Precision Compounding excludes South Carolina and Arkansas, while Belmar excludes Arkansas and Alabama. That is a pharmacy-partner list, not a guarantee that every GLP-1 formulation is available everywhere else. Confirm the exact product and pharmacy.

Do I need labs before starting?

Maybe. Midi says clinicians may order targeted labs when appropriate. It does not publish one universal GLP-1 lab panel or price, and labs are not included in the medication table.

Can I get a GLP-1 from Midi if my BMI is under 30?

A clinician must decide. Midi cites the common approved-weight-management thresholds of BMI above 30, or above 27 with a weight-related condition, but BMI is not the complete clinical decision. Compounding is not an automatic workaround for falling outside an approved indication.

Is the sublingual version as effective as an injection?

That is not publicly established for Midi's product. There is no public head-to-head evidence demonstrating equivalence between Midi's compounded sublingual route and an FDA-approved injectable. Ask what formulation is being proposed, what evidence supports the route for you, and whether approved oral Wegovy is a viable alternative.

Do I have to cancel a subscription?

Midi says there is no membership fee, so the program is not presented as a membership subscription. Medication and follow-up care can still recur. Visit changes require at least 24 hours' notice to avoid a cancellation fee; Midi's public help page does not state the amount.

How long does Midi Custom Rx shipping take?

Midi says patients can anticipate delivery within three to five business days after payment is processed. That is a provider-stated estimate, not a delivery guarantee.

What pharmacy makes Midi's compounded GLP-1?

Midi names Belmar and Precision Compounding as Custom Rx partners. Its injectable semaglutide monograph directs information-source questions to Belmar pharmacists, but the public pages do not establish which pharmacy fills every GLP-1, GLP-1/GIP, injectable, or sublingual prescription. Confirm the pharmacy on your order and label.

What happens if I stop taking a GLP-1?

Weight regain after stopping has occurred in clinical trials of approved GLP-1 therapy, but individual outcomes vary. Ask about expected treatment duration, maintenance, monitoring, and the plan if cost, access, side effects, or goals change before you begin.^[24]

Does Midi prescribe GLP-1—the bottom line?

Yes—Midi prescribes GLP-1 medication through brand-name pharmacy prescriptions and compounded injectable or sublingual routes when a clinician decides treatment is appropriate.

The reason to choose Midi is no longer simply “compounded costs less.” The lowest current approved oral Wegovy starter price is $149, below Midi's $164 minimum, although ongoing approved-product prices and eligibility change the comparison. Midi's stronger case is integrated menopause and weight care plus patient-specific flexibility when a clinician can justify it.

The damaging admissions stay in the answer because they change the decision:

• $164 is medication-only; the lowest self-pay start is $414 before labs and follow-up care.
• Compounded medication is not FDA-approved.
• Custom Rx is typically not covered by most insurance.
• The price table does not name every active ingredient.
• Pharmacy-state exclusions exist.
• Paying for the visit does not guarantee a prescription.

If you have Medicare and qualify for the Bridge, examine the $50 approved-drug route first. If your insurance covers an approved brand, price that first. If neither route meets your documented need—and Midi's integrated care model fits what you are looking for—take the six questions into the consultation and make the clinician answer them before you pay for medication.

Still not sure which HRT program is right for you?

Take our free matching quiz. Answer a few private questions about your symptoms, state, treatment preferences, risk history, and coverage. The tool shows your best-fit route and flags when online care is not the right starting point.

Find My HRT Path →

---

The HRT Index is an independent decision resource for online menopause and HRT care. This page is editorial research, not medical advice, and has not been reviewed by a clinician. See our medical review policy, editorial standards, and corrections policy. Prices, availability, insurance, and regulation change quickly; this page is re-verified monthly.

Last verified: August 2026

Which primary sources support this page?

The article is grounded in current provider, FDA, CMS, and manufacturer pages checked on August 14, 2026. Commercial terms can change without notice, so the dated sources below are the publication record—not a promise that a price or policy will remain unchanged.

¹ Midi Health, GLP-1 pricing, checked August 14, 2026.

² Midi Health, Weight management, checked August 14, 2026.

³ Midi Health Help Center, Who should take weight loss medications?, checked August 14, 2026.

⁴ Midi Health, Pricing and insurance, checked August 14, 2026.

⁵ Midi Health, Semaglutide product monograph, checked August 14, 2026.

⁶ Midi Health Help Center, Where are Midi Custom Rx prescriptions available?, checked August 14, 2026.

⁷ Midi Health Help Center, Can I use insurance, FSA, or HSA for my Midi Custom Rx prescription?, checked August 14, 2026.

⁸ Midi Health Help Center, How long does it take to receive my Midi Custom Rx or Midi Rx prescription?, checked August 14, 2026.

⁹ Midi Health Help Center, How do I cancel or reschedule a visit?, checked August 14, 2026.

¹⁰ Midi Health Help Center, How will I be billed?, checked August 14, 2026.

¹¹ NovoCare, Wegovy tablets self-pay pricing, checked August 14, 2026.

¹² NovoCare, Wegovy cash-pay terms, checked August 14, 2026.

¹³ Eli Lilly, Zepbound self-pay program, checked August 14, 2026.

¹⁴ FDA, Wegovy prescribing information, checked August 14, 2026.

¹⁵ FDA, Ozempic prescribing information, checked August 14, 2026.

¹⁶ FDA, Zepbound approval for chronic weight management and approval for obstructive sleep apnea, checked August 14, 2026.

¹⁷ FDA, Mounjaro prescribing information, checked August 14, 2026.

¹⁸ Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge information, checked August 14, 2026.

¹⁹ Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge information for providers, checked August 14, 2026.

²⁰ FDA, Compounding and FDA: Questions and Answers, checked August 14, 2026.

²¹ FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, checked August 14, 2026.

²² FDA, FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, April 30, 2026; status checked August 14, 2026.

²³ FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, updated June 15, 2026; checked August 14, 2026.

²⁴ Wilding JPH et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022).